相关实验视频

Updated: Jul 5, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

对于复发性卵巢癌的二次细胞还原手术,包括或不包括高热性腹膜内化学疗法

Dowon Lee¹, Jinhye Lee¹, Hyemin Park¹

¹Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

|January 17, 2024

概括

二次细胞还原手术 (CRS) 与高热性腹腔内化疗 (HIPEC) 并没有改善复发性卵巢癌患者的存活率. 然而,HIPEC显示出在上皮卵巢癌子组中改善无进展生存的趋势.

科学领域:

妇科瘤学妇科瘤学
手术瘤学手术瘤学
医学瘤学医学瘤学

背景情况:

再发性卵巢癌是一个重大的临床挑战.
二次细胞还原手术 (CRS) 对这些患者提供了潜在的好处.
超热腹腔内化疗 (HIPEC) 与二次性CRS结合的作用尚不清楚.

研究的目的:

在患有复发性卵巢癌的患者中,与HIPEC和没有HIPEC的二次CRS结果进行比较.
评估HIPEC对无进展生存 (PFS) 和整体生存 (OS) 的影响.

主要方法:

在2006年至2021年期间,对46名患有复发性卵巢癌的患者进行了二次CRS的回顾性评估.
患者被分为两个组:二级CRS加HIPEC (n=20) 和二级CRS-only (n=26).
卡普兰-梅尔分析被用来比较两组之间的PFS和OS.

主要成果:

在二次CRS-plus-HIPEC和二次CRS-only组之间没有观察到PFS或OS的显著差异.
中位数的PFS为32.7个月的CRS加HIPEC和25.1个月的CRS单独.
在患有上皮性卵巢癌的小组中,仅二级CRS的PFS中位数为25.1个月,而CRS加HIPEC组中位数的PFS没有达到.

结论:

在复发性卵巢癌中,与单独的二次CRS相比,二次CRS与HIPEC并没有改善生存结果.
在患上上皮质卵巢癌的患者中,当HIPEC被添加到二次CRS时,发现了改善PFS的趋势.

关键词:

复发的卵巢癌复发的卵巢癌细胞还原性手术 (CRS)上皮卵巢癌卵巢癌卵巢癌高热性腹膜内化学疗法 (HIPEC) 是一种高热性腹膜内化学疗法.

更多相关视频

Co-transplantation of Human Ovarian Tissue with Engineered Endothelial Cells: A Cell-based Strategy Combining Accelerated Perfusion with Direct Paracrine Delivery

Co-transplantation of Human Ovarian Tissue with Engineered Endothelial Cells: A Cell-based Strategy Combining Accelerated Perfusion with Direct Paracrine Delivery

Published on: May 16, 2018

Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma

Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma

Published on: January 22, 2022

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...